Related Experiment Video
Updated: Jul 10, 2026

Identification of Protein Interaction Partners in Mammalian Cells Using SILAC-immunoprecipitation Quantitative Proteomics
Published on: July 6, 2014
Identification of human cytomegalovirus UL84 virus- and cell-encoded binding partners by using proteomics analysis
Yang Gao1, Kelly Colletti, Gregory S Pari
1University of Nevada-Reno, Department of Microbiology, Howard Bldg. 210, Reno, NV 89557, USA.
Abstract:
Human cytomegalovirus (HCMV) UL84 is a phosphoprotein that shuttles from the nucleus to the cytoplasm and is required for oriLyt-dependent DNA replication and viral growth. UL84 was previously shown to interact with IE2 (IE86) in infected cells, and this interaction down-regulates IE2-mediated transcriptional activation in transient assays. UL84 and IE2 were also shown to cooperatively activate a promoter within HCMV oriLyt. UL84 alone can interact with an RNA stem-loop within oriLyt and is bound to this structure within the virion. In an effort to investigate the binding partners for UL84 in infected cells, we pulled down UL84 from protein lysates prepared from HCMV-infected human fibroblasts by using a UL84-specific antibody and resolved the immunoprecipitated protein complexes by two-dimensional gel electrophoresis. We subsequently identified individual proteins by matrix-assisted laser desorption ionization-tandem time of flight analysis. This analysis revealed that UL84 interacts with viral proteins UL44, pp65, and IE2. In addition, a number of cell-encoded proteins were identified, including ubiquitin-conjugating enzyme E2, casein kinase II (CKII), and the multifunctional protein p32. We also confirmed the interaction between UL84 and IE2 as well as the interaction of UL84 with importin alpha. UL44, pp65, and CKII interactions were confirmed to occur in infected and cotransfected cells by coimmunoprecipitation assays followed by Western blotting. Ubiquitination of UL84 occurred in the presence and absence of the proteasome activity inhibitor MG132 in infected cells. The identification of UL84 binding partners is a significant step toward the understanding of the function of this significant replication protein.
Insights
Human cytomegalovirus (HCMV) UL84 protein interacts with viral and cellular partners, including UL44, pp65, and casein kinase II. These interactions are crucial for understanding HCMV DNA replication and viral growth.
Area of Science:
- Virology
- Molecular Biology
- Cellular Biology
Background:
- Human cytomegalovirus (HCMV) UL84 is a key phosphoprotein involved in viral DNA replication and growth.
- UL84 shuttles between the nucleus and cytoplasm and interacts with viral protein IE2, modulating IE2's transcriptional activity.
- UL84 binds to an RNA stem-loop structure within the HCMV origin of lytic DNA replication (oriLyt).
Purpose of the Study:
- To identify cellular and viral binding partners of HCMV UL84 in infected cells.
- To elucidate the functional significance of UL84 interactions in the context of HCMV replication.
Main Methods:
- Immunoprecipitation of UL84 from HCMV-infected human fibroblasts.
- Two-dimensional gel electrophoresis and mass spectrometry (MALDI-TOF/TOF) for protein identification.
- Co-immunoprecipitation and Western blotting to confirm interactions.
- Analysis of UL84 ubiquitination in the presence/absence of proteasome inhibitors.
Main Results:
- UL84 was found to interact with viral proteins UL44, pp65, and IE2.
- Cellular binding partners identified include ubiquitin-conjugating enzyme E2, casein kinase II (CKII), and p32.
- Interactions with UL44, pp65, and CKII were confirmed in infected and co-transfected cells.
- UL84 ubiquitination was observed in infected cells, irrespective of proteasome activity.
Conclusions:
- The identification of UL84 binding partners provides critical insights into its role in HCMV replication.
- UL84 interacts with multiple viral and cellular proteins, suggesting a complex regulatory role in the viral life cycle.
- Further investigation of these interactions will advance the understanding of HCMV pathogenesis and therapeutic strategies.

